IMMUTEP Ltd — Regulatory Filings 2012

May 4, 2012

6-K 1 d347730d6k.htm FORM 6-K FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

Dated May 2, 2012

Commission File Number 001-35428

P RIMA B IO M ED L TD

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

Level 7, 151 Macquarie Street

Sydney, 2000 New South Wales, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): ¨

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 4, 2012

/s/ Martin Rogers
Name:	Martin Rogers
Title:	Chief Executive Officer

2

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	Press Release, dated May 2, 2012, titled “Prima BioMed to Present at the 37th Annual Deutsche Health Care
Conference”.

3